Industry
Biotechnology
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Loading...
Open
0.73
Mkt cap
162M
Volume
1.1M
High
0.75
P/E Ratio
-2.86
52-wk high
1.60
Low
0.68
Div yield
N/A
52-wk low
0.50
Portfolio Pulse from Vandana Singh
June 25, 2024 | 6:39 pm
Portfolio Pulse from Avi Kapoor
June 25, 2024 | 12:51 pm
Portfolio Pulse from Benzinga Newsdesk
June 25, 2024 | 11:46 am
Portfolio Pulse from Benzinga Newsdesk
June 25, 2024 | 9:40 am
Portfolio Pulse from Avi Kapoor
June 21, 2024 | 6:04 pm
Portfolio Pulse from Benzinga Newsdesk
June 17, 2024 | 4:45 pm
Portfolio Pulse from Benzinga Newsdesk
June 17, 2024 | 4:00 pm
Portfolio Pulse from Benzinga Insights
June 11, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
May 20, 2024 | 3:10 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 8:15 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.